When was FesariusTherapeutics founded?

FesariusTherapeutics was founded in 2017 and raised its 1st funding round 8 years after it was founded.

Where is FesariusTherapeutics located?

FesariusTherapeutics is headquartered in Brooklyn, United States.

How many employees does FesariusTherapeutics have?

As of Jun 30, 2026, the latest employee count at FesariusTherapeutics is 18.

Is FesariusTherapeutics a funded company?

FesariusTherapeutics is a funded company, having raised a total of $20M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 31, 2025.

When was the latest funding round of FesariusTherapeutics?

FesariusTherapeutics' latest funding was a $***** Series A round on Jun 10, 2026, with participation from 3 investors.

Where does FesariusTherapeutics rank among its competitors?

FesariusTherapeutics ranks 1st amongst 34 active competitors, of which 3 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was FesariusTherapeutics, which secured $20M in Jun, 2026.

Who are the top competitors of FesariusTherapeutics?

FesariusTherapeutics' top competitors include Stratum Biosciences, Hugel and BELANO Medical. Among them, FesariusTherapeutics secured the most recent funding round in June, 2026.

FesariusTherapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Dermal regeneration solutions improving patient lives through innovative hydrogel technology. This biotech startup focuses on tissue-engineered products for reconstructive and aesthetic surgery. They developed a dermal regeneration template (DRT) for wound management, addressing full-thickness skin loss. Their mission is to optimize tissue regeneration and repair with groundbreaking technologies. They aim to disrupt reconstructive surgery through quality science, compelling data, and superior products. They are committed to innovation, customer service, and improving health outcomes. Their flagship product is a novel hydrogel dermal regenerative template developed from groundbreaking technology. This solution blends scientific efficacy with clinical needs, maintaining ideal conditions in the wound bed. It supports stable vascularized tissue regeneration, mimicking the body's natural healing response. They value integrity, compassion for patient care, rigorous science, and a diverse culture. This is a B2B company.

Key Metrics

Founded Year

2017

Location

Brooklyn, United States

Stage

Series A

Total Funding

$20M in 4 rounds

Latest Funding Round

Series A, Jun 10, 2026, $*****

Investors

Jefferson Life Sciences & 4 more

Ranked

1^st among 34 active competitors

Employee Count

18 as on Jun 30, 2026

Similar Companies

Stratum Biosciences & 34 more

View FesariusTherapeutics' full profile

FesariusTherapeutics has raised a total funding of $20M over 4 rounds. Its first funding round was on Jul 31, 2025. Its latest funding round was a Series A round on Jun 10, 2026 for $*****. 3 investors participated in its latest round. FesariusTherapeutics has 5 institutional investors.

Here is the list of recent funding rounds of FesariusTherapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 10, 2026	5708424	Series A	8471209	8604505	8220631	6377832
Dec 08, 2025	2719191	Grant (prize money)	5507366	4593376	9353766	HHS
Sep 08, 2025	4048515	Grant (prize money)	4577062	4681446	7732609	HHS

Access funding benchmarks and valuations. Sign up today!

View details of FesariusTherapeutics's funding rounds and investors

The founders of FesariusTherapeutics are Yulia Sapir-Lekhovitser and Jason Spector.

Here are the details of FesariusTherapeutics' key team members:

Yulia Sapir-Lekhovitser: Co-Founder of FesariusTherapeutics.
Jason Spector: Co-Founder of FesariusTherapeutics.
Contact Info: 1 email address

View details of FesariusTherapeutics's Founder profiles and Board Members

FesariusTherapeutics' employee count trend

FesariusTherapeutics has 18 employees as of Jun 26. Here is FesariusTherapeutics's employee count trend over the years:

Employee count trend for FesariusTherapeutics

Uncover FesariusTherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of FesariusTherapeutics include Stratum Biosciences, Hugel and BELANO Medical. Here is the list of Top 10 competitors of FesariusTherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	FesariusTherapeutics 2017, Brooklyn (United States), Series A	Dermal regeneration solutions improving patient lives through innovative hydrogel technology	$20M	New York Ventures, HHS & 3 others	53/100
2nd	Stratum Biosciences 2023, New York (United States), Seed	Provider of AI-based solutions for dermatological therapies and molecular delivery across the skin	$2M	HBS Alumni Angels of Greater New York, Skin Angels	41/100
3rd	Hugel 2001, United States, Unfunded	Developer of injectables for skin rejuvenation and aesthetic treatment	-	-	36/100
4th	BELANO Medical 2010, Hennigsdorf (Germany), Seed	Developer of microbiome products for treating skin, throat, stomach, and wound care	-	b.value AG, Deutsche Biotech Innovativ AG	28/100
5th	TCI Lab 2001, Brazil, Unfunded	Manufacturer of topical dermatological creams and fluids for skin protection	-	-	28/100
6th	The Biobox 2012, Yorba Linda (United States), Unfunded	Umbilical cord lining stem cells provider	-	-	26/100
7th	PHYLA Petaluma (United States), Funding Raised	Online retailer of skincare products formulated to treat acne conditions	-	HHS	25/100
8th	Revanesse Versa 2012, Aurora (Canada), Unfunded	Developer of hyaluronic acid dermal filler for the treatment of facial wrinkles and folds	-	-	24/100
9th	Sion Medical 2001, Sderot (Israel), Unfunded	Manufacturer of medical devices for infection control, wound care, and dental	-	Kedma Capital	23/100
10th	NeuEsse 2018, Dunbar (United States), Unfunded	Developer of plant-based therapeutics for wound and skin care	-	-	22/100